Decision: Favourable

Decisions Table

Study Title:

Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced

  • NREC Code:

    22-NREC-CT-149

  • Decision:

    Favourable

  • Meeting Date:

    21/09/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Mark Doherty

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Boehringer Ingelheim International GmbH

Scroll to Top